The effects of therapy on estrogen receptors in breast cancer

Toma, S.; Leonessa, Fabio; Paridaens, Robert

doi:10.1016/0022-4731(85)90027-5

Cited by 8 publications

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tamoxifen appears to be the most consistent in this respect and, in this series, no tumour was found to have measurable oestrogen receptors if the patient was receiving tamoxifen at the time of biopsy. The precise mechanism of this action is unclear (Taylor et al, 1982;Toma et al, 1985). It may be simply that tamoxifen blocks the biochemical assay by competing with the radiolabelled oestradiol preventing it from binding to the receptor.…”

Section: Resultsmentioning

confidence: 99%

Stability of oestrogen receptor status in sequential biopsies from patients with breast cancer

Crawford

Cowan²,

Fitch³

et al. 1987

Br J Cancer

View full text Add to dashboard Cite

Summary Sequential biopsies of breast cancer tissue were obtained from a total of 210 women in order to assess any change in oestrogen receptor (ER) status arising spontaneously or as a result of intervening therapy. A combined assay measuring both cytosol and nuclear oestrogen receptors was used for all samples. One hundred and fifty-five patients had biopsies of their primary tumour and of a later loco-regional recurrence; 26 had biopsies of their primary tumour We know from previous studies that the ER status of primary breast tumours can predict the response of recurrent disease to endocrine therapy (Campbell et al., 1981;Harland et al., 1983). The extent to which ER status can change from one biopsy to another has also been previously studied with varying results (see Discussion). Hormone dependence in breast cancer can be predicted more accurately by using a combination of cytosol and nuclear oestrogen receptors than by cytosol ER alone (Leake et al., 1979). In this study we have measured both cytosol and nuclear oestrogen receptors in sequential biopsies of primary and recurrent breast cancers.Following mastectomy, many patients now receive systemic adjuvant treatment usually in the form of cytotoxic chemotherapy or endocrine therapy (usually tamoxifen). We have therefore also assessed the effects of any intervening therapy on the ER status of their recurrent disease. In addition we have examined the receptor status of tumours arising in the contralateral breast in relation to the initial disease. Patients and Methods Treatnment groupsA total of 210 patients with proven breast cancer underwent sequential biopsies of their breast cancers for ER assay, with at least 6 months between the first and second biopsies. One hundred and fifty-five patients had ER assays performed on a sample from their primary tumour and from a subsequent loco-regional recurrence. These 155 patients can be subdivided into three groups:(a) 94 patients wtho received no ssystemic anti-tumour therapy in the period between their first and second biopsies.(b) 29 patients wvho received adjuvant chemotherapj (CMF) for one year post-mastectomy. Of these, 24 had completed their course of therapy prior to developing their recurrence, leaving 5 patients still on CMF at the time of their second biopsy.(c) 32 patients who received endocrine therapy between their first and second biopsies. Twenty-one were given this on an adjuvant basis (20 received tamoxifen 20mg daily for either 2 or 5 years post-mastectomy and a single patient underwent oophorectomy followed by prednisolone). Eighteen of these 21 patients were still receiving adjuvant endocrine therapy when their recurrence developed. The remaining 11 patients in this group were receiving tamoxifen on a therapeutic basis for metastatic disease at the time of their second biopsy.Twenty-six patients had oestrogen receptor assays performed on their primary tumours and on a subsequent recurrence (or new primary) in the contralateral breast. Twenty of these patients received no systemic therap...

show abstract

Section: Resultsmentioning

confidence: 99%